Enucleation for retinoblastoma: the experience of a single center in Jordan.
Despite multiple advances in the management of retinoblastoma, enucleation remains an essential therapeutic modality. We studied patients who underwent enucleation at the King Hussein Cancer Center in Jordan. We retrospectively reviewed medical records of children with retinoblastoma who were treated at our center from June 2002 to February 2008. Twenty-eight eyes from 27 patients were enucleated. Median age at diagnosis was 1.1 years (range, 0.3-6.3 years). Twenty-six eyes (93%) had advanced disease (RE groups IV and V). Seventeen patients (61%) had unilateral retinoblastoma, and 11 (39%) had bilateral retinoblastoma. The median time from diagnosis to enucleation was 0.45 months (range, 0-45 months; mean, 4.4 months) and was longer for patients with bilateral retinoblastoma (median, 2.2 vs. 0.2 months; P = 0.034). Twenty enucleated eyes (71%) did not show high-risk pathologic features. Seventeen eyes with advanced intraocular disease were enucleated at the time of presentation, whereas chemoreduction was attempted for the other 19 eyes with advanced intraocular disease. Enucleation was then recommended for nine (47%) of those eyes. Enucleation at the time of diagnosis was feasible for most patients with advanced disease. Attempted salvage of eyes with advanced disease is justified, particularly in patients with bilateral disease. We were able to salvage almost half of these eyes. We hope our study provides new insights for counseling patients.
Sultan
Iyad
I
Department of Pediatric Oncology, King Hussein Cancer Center, Queen Rania Al Abdullah Street, P.O. Box 1269, Amman, 11941, Jordan. isultan@khcc.jo
Wilson
Matthew W
MW
Nawaiseh
Ibrahim
I
Mehyar
Mustafa
M
Kharma
Saamir
S
Al-Qudimat
Mohammed
M
Hazin
Ribhi
R
Alalami
Arwa
A
Jaradat
Imad
I
Al-Husseini
Maysa
M
Abdeen
Ghadeer
G
Rodriguez-Galindo
Carlos
C
Qaddoumi
Ibrahim
I
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002675:Child, Preschool; D015353:Eye Enucleation; D005260:Female; D006801:Humans; D007223:Infant; D007597:Jordan; D008297:Male; D019572:Retinal Neoplasms / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology / Q000601:surgery*; D012175:Retinoblastoma / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology / Q000601:surgery*; D012189:Retrospective Studies; D012307:Risk Factors; D012720:Severity of Illness Index; D013997:Time Factors
D000970:Antineoplastic Agents